Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy


Wednesday, 19 Jun 2013 08:03am EDT 

Alk Abello A/S announced that the outcome of the first of two pivotal Phase III trials with a new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases was positive. The MERIT trial meets its primary endpoint and demonstrates that the new treatment has a significant clinical effect in allergic rhinitis. The positive outcome allows for a European filing in 2014. The trial also demonstrated that the treatment was well tolerated and had a favourable safety profile. 

Company Quote

732.0
5.0 +0.69%
17 Sep 2014